Investigational drug · Phase 3
Elritercept
Also called: TAK-226, KER-050
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myelodysplastic Syndromes, Myelofibrosis, Anemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
6
Any phase or sponsor naming "Elritercept"
First trial start
2020
Aug 19, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Elritercept", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelodysplastic Syndromes
- Myelofibrosis
- Anemia
- Cytopenia
- Myelodysplastic Syndrome
Approved drugs for the same conditions: Myelodysplastic syndromes · Myelofibrosis · Anemia · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Elritercept" as an intervention, largest first.
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07623161 · 324 participants (planned) · Start Sep 10, 2026 · Primary completion Dec 7, 2029
Drug: Placebo; Elritercept · For: Myelofibrosis; Anemia
Sites: Gilbert, Arizona; Glendale, California; Whittier, California · 214 sites in all
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood TransfusionsPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07422480 · 300 participants (planned) · Start May 21, 2026 · Primary completion Apr 30, 2029
Drug: Elritercept; Epoetin Alfa · For: Myelodysplastic Syndrome; Anemia
Sites: Gilbert, Arizona; Duarte, California; Santa Rosa, California · 166 sites in all
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06499285 · 225 participants (planned) · Start May 6, 2025 · Primary completion Sep 15, 2028
Drug: Elritercept; Placebo · For: Myelodysplastic Syndromes
Sites: Duarte, California; Glendale, California; La Jolla, California · 182 sites in all
TakedaTakeda (TAK)
NCT04419649 · 210 participants (planned) · Start Aug 19, 2020 · Primary completion Oct 30, 2029
Drug: Elritercept · For: Myelodysplastic Syndromes; Cytopenia
Sites: Hot Springs, Arkansas; Duarte, California; Miami, Florida · 53 sites in all
TakedaTakeda (TAK)
NCT05037760 · 135 participants (planned) · Start Dec 16, 2021 · Primary completion Feb 28, 2028
Drug: Elritercept; Ruxolitinib · For: Myelofibrosis
Sites: Concord, Australia; Tweed Heads, Australia; Woodville South, Australia · 46 sites in all
- A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic SyndromesRecruiting
TakedaTakeda (TAK)
NCT07319845 · 42 participants (planned) · Start Apr 22, 2026 · Primary completion Jun 26, 2028
Drug: TAK-226 · For: Myelodysplastic Syndromes
Sites: Tokyo, Japan; Fukui, Japan; Hiroshima, Japan · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.
Gangat N, Guglielmelli P, Vannucchi AM, et al. · Am J Hematol 2026
- Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.
Aluri A, Kishtagari A · Semin Hematol 2026
- Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes.
Gangat N, Tefferi A · Am J Hematol 2025
- Emerging Therapeutic Approaches for Anemia in Myelofibrosis.
Chifotides HT, Duminuco A, Torre E, et al. · Curr Hematol Malig Rep 2025
- Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs.
Wei CT, Than H, Huang FJ, et al. · Hematol Oncol 2025
- Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial.
Lachey J, Rovaldi C, Bobba S, et al. · Blood Adv 2025
Also in development for Myelodysplastic Syndromes
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- OfirnoflastHT-6184Phase 22 trials
Halia Therapeutics, Inc. · Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.